Subject(s)
Fat Necrosis , Ulcer , Fat Necrosis/diagnosis , Humans , Infant, Newborn , Necrosis , Subcutaneous Fat , Subcutaneous TissueABSTRACT
First-line treatment for problematic infantile hemangiomas (IH) consists of systemic corticosteroids or, more recently, beta-blockers, while treatment failures or residual lesions may require surgical intervention. There is limited knowledge if prior medical intervention is associated with a better surgical outcome. This retrospective cohort study revealed that medical intervention, whether systemic steroids or beta-blockers, did not influence ultimate surgical outcomes when compared with patients who were not medically treated. However, patients who received prior medical treatment and those who received beta-blockers underwent surgical intervention at an earlier age.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Glucocorticoids/therapeutic use , Hemangioma/surgery , Propranolol/therapeutic use , Skin Neoplasms/surgery , Canada , Child , Child, Preschool , Cohort Studies , Female , Hemangioma/drug therapy , Humans , Infant , Male , Retrospective Studies , Skin Neoplasms/drug therapy , Treatment Failure , Treatment OutcomeABSTRACT
We describe a 5-month-old boy with clinical and histopathologic presentation of Sweet syndrome. He responded to systemic corticosteroids, with multiple flares on tapering; potassium iodide was added, which provided complete resolution of Sweet syndrome. Potassium iodide has been used in only a few cases, and no standard dosage has been established in children. We discuss calculation of a pediatric dosage for potassium iodide in Sweet syndrome.
Subject(s)
Potassium Iodide/administration & dosage , Sweet Syndrome/drug therapy , Glucocorticoids/therapeutic use , Humans , Infant , Male , Recurrence , Skin/pathology , Sweet Syndrome/diagnosis , Treatment OutcomeABSTRACT
Subcutaneous fat necrosis of the newborn (SFNN) is a rare disorder characterised by indurated plaques or nodules with or without erythema, typically distributed over the cheeks, extremities, posterior trunk, buttocks, and thighs, and appears during the first 2 weeks of life. It is commonly associated with perinatal asphyxia and, while usually self-limited, can lead to severe hypercalcemia. There is no known familial association. The present article describes a neonate with extensive disease, counterintuitive hypocalcemia, and a family history of SFNN and reviews the existing literature on SFNN.
Subject(s)
Fat Necrosis , Hypocalcemia , Panniculitis , Subcutaneous Fat/physiopathology , Female , Humans , Infant, Newborn , Skin/pathologyABSTRACT
PURPOSE OF REVIEW: Psoriasis is a multifactorial, chronic, inflammatory skin disease that may represent a therapeutic challenge in children. This review aims to provide a framework for the management of pediatric psoriasis, emphasizing in new insights and considerations for management. It will focus on new disease associations and innovative treatment modalities that challenge current approach of psoriasis in children. RECENT FINDINGS: There is an increasing body of literature both in adults and in children linking psoriasis with different comorbidities. This new evidence points to the need of addressing psoriasis as a systemic disease and suggests the need for screening and creating awareness of possible associations. In a similar manner, newer medications are also being investigated in children. Recent publications report on the efficacy and safety of biologics for psoriasis in pediatric patients. SUMMARY: The review provides better understanding of present and future risks of untreated and uncontrolled psoriasis in children and at the same time the benefits and risks of new treatments available.